Abstract
Introduction. Medullary thyroid carcinoma (MTC) is a rare and aggressive malignancy, accounting for 2–5% of all thyroid cancers. Aim. This study examined the epidemiological profile of MTC in the Tyumen Region (Russia) and evaluated the effectiveness and tolerability of multikinase inhibitors (MKIs) in MTC therapy. Materials and methods. The analysis included 69 patients with MTC treated between 2017 and 2025. Patient age ranged from 39 to 78 years (median 57). Sonographic characteristics of thyroid nodules were classified according to the EU-TIRADS. Cytological evaluation of fine-needle aspiration samples followed the Bethesda Thyroid Classification (2009, 2017, 2023). Survival outcomes were calculated using the Kaplan–Meier method. Serum calcitonin (CT) and carcinoembryonic antigen (CEA) levels were measured by electrochemiluminescence. RET mutation testing was performed on blood samples and, in one case, on surgical tissue. Results . Between 2017 and 2025, peak MTC incidence in the Tyumen Region occurred in 2021 and 2024, reaching 0.65 and 0.74 per 100,000 population, respectively. During cabozantinib therapy, mean survival was 19.30 months (95% CI 14.45–21.39), with a median of 17.01 months. For vandetanib in first-line therapy, mean survival was 18 months (95% CI 12.57–23.59), with a median of 14.00 months (95% CI 12.46–20.55). The objective response rate was 29.4% with vandetanib and 36.8% with cabozantinib. The most frequent adverse events were arterial hypertension with vandetanib, palmar-plantar erythrodysesthesia with cabozantinib, and toxic hepatitis with selpercatinib. Discussion. This retrospective analysis demonstrates the effectiveness and safety of MKIs in routine clinical practice. Cabozantinib showed superior survival outcomes and objective response rates compared to vandetanib. The observed adverse events were expected and manageable. The findings are consistent with published clinical evidence. Conclusion . Given the aggressive nature of MTC, continuous monitoring of disease progression is essential. In cases of progression, MKI therapy should be considered, with careful evaluation of potential toxicity in relation to individual treatment goals.

This publication has 28 references indexed in Scilit: